CN117598987A - 一种立他司特滴眼液及其制备方法 - Google Patents
一种立他司特滴眼液及其制备方法 Download PDFInfo
- Publication number
- CN117598987A CN117598987A CN202311405464.6A CN202311405464A CN117598987A CN 117598987 A CN117598987 A CN 117598987A CN 202311405464 A CN202311405464 A CN 202311405464A CN 117598987 A CN117598987 A CN 117598987A
- Authority
- CN
- China
- Prior art keywords
- mixed solution
- osmotic pressure
- vitamin
- eye
- polyvinyl alcohol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003889 eye drop Substances 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 229940012356 eye drops Drugs 0.000 title claims description 24
- 239000004372 Polyvinyl alcohol Substances 0.000 claims abstract description 20
- 229920002451 polyvinyl alcohol Polymers 0.000 claims abstract description 20
- 235000012680 lutein Nutrition 0.000 claims abstract description 17
- 229960005375 lutein Drugs 0.000 claims abstract description 17
- 239000001656 lutein Substances 0.000 claims abstract description 17
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims abstract description 17
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims abstract description 17
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims abstract description 17
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims abstract description 17
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract description 16
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims abstract description 16
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract description 16
- 229940045997 vitamin a Drugs 0.000 claims abstract description 14
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims abstract description 13
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims abstract description 13
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract description 13
- 235000019155 vitamin A Nutrition 0.000 claims abstract description 13
- 239000011719 vitamin A Substances 0.000 claims abstract description 13
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000008055 phosphate buffer solution Substances 0.000 claims abstract description 6
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract description 5
- 235000019158 vitamin B6 Nutrition 0.000 claims abstract description 5
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 5
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 5
- 239000011259 mixed solution Substances 0.000 claims description 54
- 239000000243 solution Substances 0.000 claims description 36
- 230000003204 osmotic effect Effects 0.000 claims description 29
- 238000003756 stirring Methods 0.000 claims description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 18
- 239000008213 purified water Substances 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 9
- 229920001684 low density polyethylene Polymers 0.000 claims description 9
- 239000004702 low-density polyethylene Substances 0.000 claims description 9
- 239000011780 sodium chloride Substances 0.000 claims description 9
- 229930003270 Vitamin B Natural products 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- LEAHFJQFYSDGGP-UHFFFAOYSA-K trisodium;dihydrogen phosphate;hydrogen phosphate Chemical compound [Na+].[Na+].[Na+].OP(O)([O-])=O.OP([O-])([O-])=O LEAHFJQFYSDGGP-UHFFFAOYSA-K 0.000 claims description 8
- 235000019156 vitamin B Nutrition 0.000 claims description 8
- 239000011720 vitamin B Substances 0.000 claims description 8
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 4
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 4
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 4
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 229960004641 rituximab Drugs 0.000 claims description 3
- 238000007789 sealing Methods 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- 239000008363 phosphate buffer Substances 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 abstract description 55
- 230000028327 secretion Effects 0.000 abstract description 13
- 230000001105 regulatory effect Effects 0.000 abstract description 12
- 210000004087 cornea Anatomy 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 9
- 230000002757 inflammatory effect Effects 0.000 abstract description 7
- 208000005494 xerophthalmia Diseases 0.000 abstract description 7
- 206010061218 Inflammation Diseases 0.000 abstract description 6
- 208000002193 Pain Diseases 0.000 abstract description 6
- 230000004054 inflammatory process Effects 0.000 abstract description 6
- 239000012530 fluid Substances 0.000 abstract description 4
- 229940088594 vitamin Drugs 0.000 abstract description 4
- 229930003231 vitamin Natural products 0.000 abstract description 4
- 235000013343 vitamin Nutrition 0.000 abstract description 4
- 239000011782 vitamin Substances 0.000 abstract description 4
- 238000013329 compounding Methods 0.000 abstract description 3
- 230000006378 damage Effects 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 description 17
- 239000013641 positive control Substances 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 10
- 238000000465 moulding Methods 0.000 description 9
- 238000010186 staining Methods 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 210000004561 lacrimal apparatus Anatomy 0.000 description 6
- 210000001742 aqueous humor Anatomy 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 4
- 206010013774 Dry eye Diseases 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- NJDNXYGOVLYJHP-UHFFFAOYSA-L disodium;2-(3-oxido-6-oxoxanthen-9-yl)benzoate Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=CC(=O)C=C2OC2=CC([O-])=CC=C21 NJDNXYGOVLYJHP-UHFFFAOYSA-L 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 238000006748 scratching Methods 0.000 description 3
- 230000002393 scratching effect Effects 0.000 description 3
- 208000028006 Corneal injury Diseases 0.000 description 2
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 2
- 238000005299 abrasion Methods 0.000 description 2
- 229910017052 cobalt Inorganic materials 0.000 description 2
- 239000010941 cobalt Substances 0.000 description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 206010001526 Air embolism Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010984 Corneal abrasion Diseases 0.000 description 1
- 206010011013 Corneal erosion Diseases 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- 206010052140 Eye pruritus Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- 206010027146 Melanoderma Diseases 0.000 description 1
- 206010052143 Ocular discomfort Diseases 0.000 description 1
- TVQZAMVBTVNYLA-UHFFFAOYSA-N Pranoprofen Chemical compound C1=CC=C2CC3=CC(C(C(O)=O)C)=CC=C3OC2=N1 TVQZAMVBTVNYLA-UHFFFAOYSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- VYGQUTWHTHXGQB-UHFFFAOYSA-N Retinol hexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000607 artificial tear Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019564 dysgeusia Nutrition 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 231100000013 eye irritation Toxicity 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 238000012757 fluorescence staining Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229940125798 integrin inhibitor Drugs 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229960003101 pranoprofen Drugs 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 229940108325 retinyl palmitate Drugs 0.000 description 1
- 235000019172 retinyl palmitate Nutrition 0.000 description 1
- 239000011769 retinyl palmitate Substances 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明提供了一种立他司特滴眼液及其制备工艺,该立他司特滴眼液包括如下质量百分比的组分:立他司特5%、聚乙烯醇1.5%、维生素A 0.03~0.06%、维生素B6 0.05~0.07%、叶黄素1~3%、海藻糖0.01~0.02%,余量为磷酸盐缓冲液。本发明的立他司特滴眼液通过复配特定比例的立他司特、聚乙烯醇及海藻糖,能够有效改善兔眼泪液分泌量,增强泪膜稳定性并减轻角膜损伤,并调节兔眼炎症因子水平,减轻炎症,有效治疗兔实验性干眼症;添加的维生素及叶黄素使其具有良好的使用感,不会造成点滴处刺痛,副作用轻微,能够提升患者顺应性。
Description
技术领域
本发明涉及药学领域,特别涉及一种立他司特滴眼液,该滴眼液用于治疗干眼症。
背景技术
干眼症是由于长期缺乏维生素A、代谢性疾病、慢性炎症等多种原因造成泪液质或量发生改变,造成眼部一系列不适及眼表组织发生病理改变。干眼症在症状上主要表现为眼睛疲倦干涩、发痒有异物感、怕光、灼伤感等,若不及时控制会导致角质层受损,损害患者视功能。泪膜不稳定、眼表炎症反应、泪液渗透压升高、眼表损伤等均为干眼症发病机制。目前,临床上治疗干眼症的方法有补充泪液、调节泪液渗透压、抑制眼表炎症反应等,均有一定疗效。
药物治疗中,人工泪液、维生素A棕榈酸酯眼用凝胶、普拉洛芬滴眼液等是常用药物。这些药物主要用于改善泪膜功能、减轻炎症反应、改善眼表环境等。立他司特(lifitegrast)是一种新型小分子整合素抑制剂,通过抑制淋巴细胞功能相关抗原1(LFA-1)与细胞间粘附分子1(ICAM-1)的结合,从而减少由T淋巴细胞介导的炎症水平。2016年,FDA批准其用于干眼症的治疗。然而,在临床试验中,5~25%的患者报告其会导致点滴部位刺痛、味觉障碍及视力下降;另有1~5%患者报告了视力模糊,结膜充血,眼刺激,头痛,流泪增加,眼排泄物,眼不适,眼瘙痒和窦炎等其他不良反应。
然而,现有技术中,尚没有能够减少这些不良反应发生的立他司特滴眼液。因此,开发一种治疗效果好、不良反应低、安全性高的立他司特滴眼液是本领域亟待解决的技术问题。
发明内容
有鉴于此,本发明提供一种立他司特滴眼液及其制备方法。
本发明技术方案如下:
一种立他司特滴眼液,包括如下质量百分比的组分:立他司特5%、聚乙烯醇1.5%、维生素A 0.03~0.06%、维生素B6 0.05~0.07%、叶黄素1~3%、海藻糖0.01~0.02%,余量为磷酸盐缓冲液。
进一步的,上述的滴眼液,包括如下质量百分比的组分:立他司特5%、聚乙烯醇1.5%、维生素A 0.05%、维生素B6 0.06%、叶黄素2%、海藻糖0.015%,余量为磷酸盐缓冲液。
进一步的,上述的滴眼液,其中,磷酸盐缓冲液由纯化水、磷酸二氢钠、磷酸氢二钠、氯化钠组成。
本发明还提供一种上述任一项的立他司特滴眼液制备方法,包括以下步骤:
S1.将立他司特、聚乙烯醇和海藻糖混合分散至纯化水中,搅拌混合液,同时调节混合液pH、渗透压,至形成均质的粘溶液;
S2.向S1所得粘溶液中加入维生素A、维生素B6、叶黄素,搅拌均匀;
S3.对S2所得粘溶液高温灭菌,无菌条件下将灭菌后的粘溶液灌封至预先灭菌的0.2mL LDPE管中,制得所述立他司特滴眼液。
进一步的,上述的制备方法,其中,步骤S1中,调节pH、渗透压后所得粘溶液pH为6.5~7.5,渗透压为295~309mOsm/L。
进一步的,上述的制备方法,其中,步骤S1中,调节pH步骤如下:
测量混合液pH;
如pH<6.5,向混合液中加入pH=7.2的磷酸二氢钠-磷酸氢二钠混合溶液,至混合液pH≥6.5;
如pH>7.5,向混合液中加入pH=6.8的磷酸二氢钠-磷酸氢二钠混合溶液,至混合液pH≤7.5。
进一步的,上述的制备方法,其中,步骤S1中,调节渗透压步骤如下:
测量混合液渗透压;
如渗透压<295mOsm/L,向混合液中加入氯化钠,至混合液渗透压≥295mOsm/L;
如渗透压>309mOsm/L,向混合液中加入纯化水,至混合液渗透压≤309mOsm/L。
进一步的,上述的制备方法,其中,步骤S1中,调节混合液pH先于调节混合液渗透压进行。
进一步的,上述的制备方法,其中,步骤S2中,搅拌转速80rpm,搅拌时长30分钟。
进一步的,上述的制备方法,其中,步骤S3中,高温灭菌温度121℃,时间30分钟。
本发明的有益效果如下:本发明制得的立他司特滴眼液通过复配特定比例的立他司特、聚乙烯醇及海藻糖,能够有效改善兔眼泪液分泌量,增强泪膜稳定性并减轻角膜损伤,并调节兔眼炎症因子水平,减轻炎症,有效治疗兔实验性干眼症;添加的维生素及叶黄素使其具有良好的使用感,不会造成点滴处刺痛,副作用轻微,能够提升患者顺应性。
具体实施方式
下述实施例中所使用的实验方法如无特殊说明,均为常规方法;下述实施例中所用的试剂、材料等,如无特殊说明,以下实施例中使用的原料和试剂均为市售商品,或者可以通过已知方法制备。下列实施例中未注明具体条件的实验方法,通常按照常规条件如Sambrook等人,分子克隆:实验室手册(New York:Cold SpringHarbor Laboratory Press,1989)中所述的条件,或按照制造厂商所建议的条件。
实施例1
取立他司特5g、聚乙烯醇1.5g和海藻糖0.015g混合分散到纯化水中至总重量为100g,搅拌溶解,同时测量混合液pH=5.4、渗透压为287mOsm/L,加入pH=7.2的磷酸二氢钠-磷酸氢二钠混合溶液调节混合液pH至6.8,随后加入氯化钠调节混合液渗透压为302mOsm/L,充分溶解均匀至得到澄清的均质粘溶液后,向粘溶液中加入维生素A 0.05g、维生素B6 0.06g、叶黄素2g,转速80rpm,搅拌30分钟,至再次得到澄清的均质粘溶液后,将粘溶液在121℃下加热30分钟,冷却至室温,在负压和无菌条件下将杀菌后的粘溶液灌装至预先灭菌的0.2mL LDPE管中,制得立他司特滴眼液。
实施例2
取立他司特5g、聚乙烯醇1.5g和海藻糖0.01g混合分散到纯化水中至总重量为100g,搅拌溶解,同时测量混合液pH=7.7、渗透压为315mOsm/L,加入pH=6.8的磷酸二氢钠-磷酸氢二钠混合溶液调节混合液pH至7.2,随后加入纯化水调节混合液渗透压为299mOsm/L,充分溶解均匀至得到澄清的均质粘溶液后,向粘溶液中加入维生素A 0.03g、维生素B6 0.05g、叶黄素1g,转速80rpm,搅拌30分钟,至再次得到澄清的均质粘溶液后,将粘溶液在121℃下加热30分钟,冷却至室温,在负压和无菌条件下将杀菌后的粘溶液灌装至预先灭菌的0.2mL LDPE管中,制得立他司特滴眼液。
实施例3
取立他司特5g、聚乙烯醇1.5g和海藻糖0.02g混合分散到纯化水中至总重量为100g,搅拌溶解,同时测量混合液pH=6.2、渗透压为285mOsm/L,加入pH=7.2的磷酸二氢钠-磷酸氢二钠混合溶液调节混合液pH至7.0,随后加入氯化钠调节混合液渗透压为303mOsm/L,充分溶解均匀至得到澄清的均质粘溶液后,向粘溶液中加入维生素A 0.06g、维生素B6 0.07g、叶黄素3g,转速80rpm,搅拌30分钟,至再次得到澄清的均质粘溶液后,将粘溶液在121℃下加热30分钟,冷却至室温,在负压和无菌条件下将杀菌后的粘溶液灌装至预先灭菌的0.2mL LDPE管中,制得立他司特滴眼液。
对比例1
取立他司特5g和海藻糖0.015g混合分散到纯化水中至总重量为100g,搅拌溶解,同时测量混合液pH=5.4、渗透压为287mOsm/L,加入pH=7.2的磷酸二氢钠-磷酸氢二钠混合溶液调节混合液pH至6.8,随后加入氯化钠调节混合液渗透压为302mOsm/L,充分溶解均匀至得到澄清的均质粘溶液后,向粘溶液中加入维生素A 0.05g、维生素B6 0.06g、叶黄素2g,转速80rpm,搅拌30分钟,至再次得到澄清的均质粘溶液后,将粘溶液在121℃下加热30分钟,冷却至室温,在负压和无菌条件下将杀菌后的粘溶液灌装至预先灭菌的0.2mL LDPE管中,制得立他司特滴眼液。本法制得的立他司特滴眼液不含聚乙烯醇。
对比例2
取立他司特5g、聚乙烯醇1.5g和海藻糖0.015g混合分散到纯化水中至总重量为100g,搅拌溶解,同时测量混合液pH=5.4、渗透压为287mOsm/L,加入pH=7.2的磷酸二氢钠-磷酸氢二钠混合溶液调节混合液pH至6.8,随后加入氯化钠调节混合液渗透压为302mOsm/L,充分溶解均匀至得到澄清的均质粘溶液后,向粘溶液中加入维生素A 0.05g、维生素B6 0.06g、叶黄素2g,转速80rpm,搅拌30分钟,至再次得到澄清的均质粘溶液后,将粘溶液在121℃下加热30分钟,冷却至室温,在负压和无菌条件下将杀菌后的粘溶液灌装至预先灭菌的0.2mL LDPE管中,制得立他司特滴眼液。本法制得的立他司特滴眼液不含维生素和叶黄素。
对比例3
取立他司特5g和聚乙烯醇1.5g混合分散到纯化水中至总重量为100g,搅拌溶解,同时测量混合液pH=5.4、渗透压为287mOsm/L,加入pH=7.2的磷酸二氢钠-磷酸氢二钠混合溶液调节混合液pH至6.8,随后加入氯化钠调节混合液渗透压为302mOsm/L,充分溶解均匀至得到澄清的均质粘溶液后,向粘溶液中加入维生素A 0.05g、维生素B6 0.06g、叶黄素2g,转速80rpm,搅拌30分钟,至再次得到澄清的均质粘溶液后,将粘溶液在121℃下加热30分钟,冷却至室温,在负压和无菌条件下将杀菌后的粘溶液灌装至预先灭菌的0.2mL LDPE管中,制得立他司特滴眼液。本法制得的立他司特滴眼液不含海藻糖。
性能测试
(1)外观
室温下肉眼观察实施例1-3及对比例1-3制得的立他司特滴眼液,并拆开LDPE管试滴。
表1各样品制备工艺
如上表所示,各实施例及对比例所制得的立他司特滴眼液均为无色澄明液体,但其粘稠度与聚乙烯醇含量相关,不含聚乙烯醇的立他司特滴眼液粘度较低。
(2)动物实验
选取清洁级成年新西兰白兔(2.5~3kg)进行实验,雌雄各半,根据体重随机分组,每组4只。在实验前用裂隙灯显微镜检查实验动物无眼部异常。分组给药方案如下表。
表2分组给药方案
测试项目:
1)Schirmer试纸测定兔眼泪液分泌量
实验第0、7、14、21、28天时,使用Schirmer试纸测量兔眼泪液分泌量。具体方法为:将Schirmer纸条插入兔眼的下眼睑中、外三分之一交界处附近的结膜囊位置,5min后读取湿纸条的长度(mm)。为保证实验结果的客观性和准确性,每次每只兔子双眼均由同一人完成。
2)荧光素钠试纸测定兔眼泪膜的稳定性及兔眼角膜染色评分
分别于实验第0、7、14、21、28天进行兔眼泪膜破裂时间测定。手持荧光素钠试纸底端,在试纸表面滴加2滴生理盐水稀释,将试纸头部置于兔眼的下结膜囊内5s后取出,手动闭合眼睑数次,使荧光素钠均匀分布在眼表,在裂隙灯的钴蓝光下用宽裂隙带观察,最后一次瞬目后睁眼至角膜出现第1个黑斑的时间为泪膜破裂时间,连续测量3次取平均值。
将生理盐水稀释后的试纸,轻抚于兔眼表面,使荧光素钠分布均匀,2min后,在裂隙灯的钴蓝光下用宽裂隙带观察并进行评分。本次实验采用NEI角膜荧光染色评分分级法,NEI干眼症临床试验研讨会推荐的分级系统将角膜分为5个区:中央区、上区、颞区、鼻区和下区。对于每个区域,角膜荧光素染色的数量在0到3的范围内分级:0级正常或阴性裂隙灯发现;1级轻度或浅层点画;2级中度或点状染色,包括角膜表面磨损;3级严重磨损或角膜侵蚀、角膜深层磨损或复发性侵蚀。最大分数为15分。
3)ELISA法测定兔眼泪腺、房水中TNF-α和IL-6表达水平
最后一次给药后4h,空气栓塞法处死实验兔,取兔眼泪腺、房水,经匀浆机匀浆后,取上清液,严格按照各试剂盒说明书测定TNF-α和IL-6的含量。
测试结果如下表3-1至3-4所示。
表3-1兔眼泪液分泌量检测结果
表3-2兔眼泪膜稳定性检测结果
表3-3兔眼角膜染色评分结果
表3-4兔眼TNF-α和IL-6表达水平测试结果
说明:采用GraphPad Prism 8软件进行统计学分析。P<0.05,表示差异具有显著性。
如上表3-1所示,实验全过程中(0-28d),空白组兔的泪液分泌量测得结果约为20mm;造模过程中(0-14d),模型组及各实验组、阳性对照组兔泪液分泌量随造模推进而下降,14d时,与空白组兔有显著差异(p<0.05),证明造模成功;治疗过程中(15-28d),模型组兔泪液分泌量有小幅度回升,反应了兔眼的自我修复作用;实验组1-3的兔于21d时泪液分泌量即恢复正常(与空白组相比,p>0.05);实验组5的兔在28d时泪液分泌量回升至正常水平(与空白组相比,p>0.05);实验组4、6及阳性对照组1-2的兔在治疗过程中泪液分泌量有不同程度的回升,但未能恢复正常(与空白组相比,p<0.05);
如上表3-2所示,实验全过程中(0-28d),空白组兔的泪膜破裂时间约为6.1s;造模过程中(0-14d),模型组及各实验组、阳性对照组兔的泪膜破裂时间随造模推进而下降,14d时,与空白组兔有显著差异(p<0.05),证明造模成功;治疗过程中(15-28d),模型组兔的泪膜破裂时间有小幅度回升,反应了兔眼的自我修复作用;实验组1-3的兔于21d时泪膜破裂时间即恢复正常(与空白组相比,p>0.05);实验组5的兔在28d时泪膜破裂时间回升至正常水平(与空白组相比,p>0.05);实验组4、6及阳性对照组1-2的兔在治疗过程中泪膜破裂时间有不同程度的回升,但未能恢复正常(与空白组相比,p<0.05)。
如上表3-3所示,实验全过程中(0-28d),空白组兔的眼角膜染色评分约为0.2;造模过程中(0-14d),模型组及各实验组、阳性对照组兔的眼角膜染色评分随造模推进而上升,14d时,与空白组兔有显著差异(p<0.05),证明造模成功;治疗过程中(15-28d),模型组兔的眼角膜染色评分有小幅度下降,反应了兔眼的自我修复作用;实验组1-3的兔于21d时眼角膜染色评分下降至约5.5,于28d时眼角膜染色评分下降至约4.7;实验组4-6及阳性对照组1-2的兔在治疗过程中的眼角膜染色评分有不同程度的下降,但下降幅度低于实验组1-3。
如上表3-4所示,实验结束后(28d),与空白组兔相比,模型组兔房水、泪腺中的炎症因子水平明显升高(p<0.05);与模型组兔相比,各实验组及阳性对照组1兔的房水、泪腺中的炎症因子水平均明显下降(p<0.05),阳性对照组1兔的房水、泪腺中的炎症因子水平没有改善(p>0.05);在泪腺TNF-α水平上,各实验组及阳性对照组1采用的药物起到的作用效果相仿,均下降至接近正常水平(与空白组相比,p>0.05);在其他炎症因子水平中,实验组1-3、5的下降幅度显著优于其他实验组及阳性对照组1(p<0.05)。
此外,在治疗过程中,实验组4-6及阳性对照组1的兔出现抓挠用药眼的行为,其中阳性对照组1的兔抓挠行为最严重,实验组5与之相仿,实验组4、6抓挠行为相对较少。
上述测试结果说明,本发明制得的立他司特滴眼液能够有效改善兔眼泪液分泌量,增强泪膜稳定性并减轻角膜损伤,并调节兔眼炎症因子水平,减轻炎症,有效治疗兔实验性干眼症,且其使用感佳,不会造成点滴处刺痛,副作用轻微,能够提升患者顺应性。通过与对比例制得的立他司特滴眼液及市售立他司特滴眼液、聚乙烯醇滴眼液比较可知,通过将立他司特与特定比例的聚乙烯醇和海藻糖复配,能够显著提高对干眼症的治疗效果;通过加入一定量维生素、叶黄素,能够减轻家兔由于使用立他司特滴眼液的疼痛感,在有聚乙烯醇存在时,能够进一步减轻疼痛。
尽管上面已经示出和描述了本申请的实施例,理解的是,上述实施例是示例性的,不能理解为对本申请的限制,本领域的普通技术人员在本申请的范围内对上述实施例进行变化、修改、替换和变型。
Claims (10)
1.一种立他司特滴眼液,其特征在于,包括如下质量百分比的组分:立他司特5%、聚乙烯醇1.5%、维生素A 0.03~0.06%、维生素B6 0.05~0.07%、叶黄素1~3%、海藻糖0.01~0.02%,余量为磷酸盐缓冲液。
2.根据权利要求1所述的滴眼液,其特征在于,包括如下质量百分比的组分:立他司特5%、聚乙烯醇1.5%、维生素A 0.05%、维生素B6 0.06%、叶黄素2%、海藻糖0.015%,余量为磷酸盐缓冲液。
3.根据权利要求1或2所述的滴眼液,其特征在于,所述磷酸盐缓冲液由纯化水、磷酸二氢钠、磷酸氢二钠、氯化钠组成。
4.一种权利要求1-3任一项所述的立他司特滴眼液制备方法,包括以下步骤:
S1.将立他司特、聚乙烯醇和海藻糖混合分散至纯化水中,搅拌混合液,同时调节混合液pH、渗透压,至形成均质的粘溶液;
S2.向S1所得粘溶液中加入维生素A、维生素B6、叶黄素,搅拌均匀;
S3.对S2所得粘溶液高温灭菌,无菌条件下将灭菌后的粘溶液灌封至预先灭菌的0.2mLLDPE管中,制得所述立他司特滴眼液。
5.根据权利要求4所述的制备方法,其特征在于,步骤S1中,调节pH、渗透压后所得粘溶液pH为6.5~7.5,渗透压为295~309mOsm/L。
6.根据权利要求4或5所述的制备方法,其特征在于,步骤S1中,调节pH步骤如下:
测量混合液pH;
如pH<6.5,向混合液中加入pH=7.2的磷酸二氢钠-磷酸氢二钠混合溶液,至混合液pH≥6.5;
如pH>7.5,向混合液中加入pH=6.8的磷酸二氢钠-磷酸氢二钠混合溶液,至混合液pH≤7.5。
7.根据权利要求4或5所述的制备方法,其特征在于,步骤S1中,调节渗透压步骤如下:
测量混合液渗透压;
如渗透压<295mOsm/L,向混合液中加入氯化钠,至混合液渗透压≥295mOsm/L;如渗透压>309mOsm/L,向混合液中加入纯化水,至混合液渗透压≤309mOsm/L。
8.根据权利要求4或5所述的制备方法,其特征在于,步骤S1中,调节混合液pH先于调节混合液渗透压进行。
9.根据权利要求4所述的制备方法,其特征在于,步骤S2中,搅拌转速80rpm,搅拌时长30分钟。
10.根据权利要求4所述的制备方法,其特征在于,步骤S3中,高温灭菌温度121℃,时间30分钟。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311405464.6A CN117598987A (zh) | 2023-10-27 | 2023-10-27 | 一种立他司特滴眼液及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311405464.6A CN117598987A (zh) | 2023-10-27 | 2023-10-27 | 一种立他司特滴眼液及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117598987A true CN117598987A (zh) | 2024-02-27 |
Family
ID=89946987
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311405464.6A Pending CN117598987A (zh) | 2023-10-27 | 2023-10-27 | 一种立他司特滴眼液及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117598987A (zh) |
-
2023
- 2023-10-27 CN CN202311405464.6A patent/CN117598987A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2019261598B2 (en) | Use of pilocarpine hydrochloride for the treatment of ocular conditions | |
CN111991415B (zh) | 一种眼部护理组合物及其制备方法和用途 | |
US20230241042A1 (en) | Use of penehyclidine in treatment or prevention of vision-impairing eye diseases | |
JP2021191802A (ja) | 眼疾患を処置するためのオキシメタゾリン組成物および方法 | |
CN111803441A (zh) | 一种含0.01%阿托品的玻璃酸钠滴眼液及其制备方法 | |
CN110013498A (zh) | 一种含盐酸奥洛他定的滴眼液及其制备方法 | |
CN102008488B (zh) | 一种曲安奈德眼用制剂及其制备方法 | |
CN110833526B (zh) | 一种防治青少年近视的眼用制剂及其制备方法 | |
CN116139083A (zh) | 一种低浓度阿托品纳米乳剂及其制备方法和应用 | |
CN117598987A (zh) | 一种立他司特滴眼液及其制备方法 | |
CN112891326B (zh) | 一种载有那他霉素的海藻酸凝胶药膜及其制备方法 | |
CN105213418B (zh) | 一种眼科术前用复方滴眼液及其制备方法 | |
CN109453151B (zh) | 眼用药物组合物、其制备方法及其应用 | |
CN108066282B (zh) | 一种左氧氟沙星滴眼液及其制备方法 | |
CN102579492A (zh) | 一种含小牛血去蛋白提取物的玻璃酸钠滴眼液及其制备方法 | |
US20110268817A1 (en) | Compounds useful for the prevention or treatment of accomodative asthenopia | |
CN109549922B (zh) | 一种托吡卡胺眼用组合物及其制备方法与应用 | |
EP2783695A1 (en) | Physiological supplement or medicament for ophthalmic use containing L-carnitine or alkanoyl L-carnitines in combination with eledoisin | |
CN100362991C (zh) | 一种眼科用药物组合物 | |
Berggren | Individual responsiveness to topical pilocarpine and the effects of variations in application technique | |
TW470648B (en) | A pharmaceutical composition containing albumin as an active ingredient for treating cornea disorder and dry eyes | |
CN115624521A (zh) | 可修复角膜损伤的青少年近视防控滴眼液及其制备方法 | |
CN116459251A (zh) | 一种含西维美林的眼用制剂及其制备方法和应用 | |
CN115068456A (zh) | 二甲双胍在制备预防、治疗眼部疾病的药物中的用途及其剂型和制备方法 | |
CN117503691A (zh) | 一种具有减轻老视作用的长效眼用制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication |